Hirata Y, Yamada A, Niikura R, et al. - Whether rifabutin‐based triple therapy with vonoprazan is efficacious and safe for refractory H pylori infection was determined in this prospective study. For inclusion, experts recruited patients who failed H pylori eradication by clarithromycin‐based first‐line, metronidazole‐based second‐line, and sitafloxacin‐based third‐line therapies. Informed consent was taken and thereafter eradication therapy with vonoprazan (20 mg), amoxicillin (750 mg), and rifabutin (150 mg) twice daily for 10 days was administered. This study included 19 patients. Per findings, 10‐day rifabutin with amoxicillin and vonoprazan triple therapy seemed to be effective as well as safe for refractory H pylori infections. However, high eradication rates with vonoprazan amoxicillin dual therapy have been shown in recent publications, so, confirmation will need future investigations comparing experts' novel therapy with vonoprazan‐amoxicillin dual with similar doses and duration and with vonoprazan‐rifabutin dual therapy.